Second Line Treatments in Advanced Platinum-Resistant Non Small Cell Lung Cancer. A Critical Review of Literature

摘要: In the last 10 years medical approach to platinum-resistant Non Small Cell Lung Cancer (NSCLC) has radically changed, passing from a lack of evidence any primary treatment against tumor, identification chemotherapy or EGFR inhibitors as gold standard for clinical practice. Eight randomized trials support efficacy second-line treatments NSCLC, and docetaxel, pemetrexed erlotinib are most effective options However, many aspects remain still undefined: Can with be considered all patients consequently should treated at least one these options? Are benefits enough justify side effects observed chemotherapeutic schedule preferred others either safety profile? new an innovation in they used NSCLC? A systematic review critical analysis results were performed aim clarify real meaning advanced, NSCLC.